Table 2.
Univariate and multivariate cox regression model for DFS in matched cohort.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI for HR) | P | HR (95% CI for HR) | P | |
| Sex | ||||
| Female/Male | 0.934 (0.715–1.219) | 0.615 | ||
| Age | ||||
| ≤60/>60 | 0.874 (0.668–1.140) | 0.317 | ||
| Tumor size | ||||
| ≤4/4 cm | 1.632 (1.228–2.170) | <0.001 | 2.050 (1.506–2.791) | <0.001 |
| 8th AJCC stage | ||||
| I, IIa/IIb,III | 1.406 (1.055–1.874) | 0.020 | 1.892 (1.343-2.665) | <0.001 |
| Positive LN ratio | ||||
| ≤0.02/0.02 | 1.462 (1.071–1.997) | 0.017 | 1.264 (0.899–1.777) | 0.178 |
| Soft tissue invasion | ||||
| Negative/Positive | 1.033 (0.752–1.420) | 0.840 | ||
| Vessel invasion | ||||
| Negative/Positive | 1.021 (0.698–1.493) | 0.916 | ||
| Differentiation | ||||
| Poor/Well | 0.816 (0.580–1.147) | 0.241 | ||
| CA19-9 | ||||
| ≤200/>200 U/ml | 1.297 (0.994–1.694) | 0.056 | ||
| CEA | ||||
| ≤3.5/>3.5 ng/ml | 0.973 (0.746–1.270) | 0.842 | ||
| iPNI | ||||
| Negative/Positive | 1.048 (0.800–1.374) | 0.732 | ||
| Postoperative chemotherapy | ||||
| No/Yes | 0.796 (0.594–1.065) | 0.125 | ||
| Curability | ||||
| R0/R1 | 1.414 (1.081–1.850) | 0.012 | 1.739 (1.311–2.305) | <0.001 |
AJCC, American Joint Committee on Cancer Staging; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HR, hazard ratio; iPNI, imaging perineural invasion; LN, lymph node.